From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Stock Information for Cel-Sci Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cel-Sci Corporation

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
CEL-SCI Announces Closing of Public Offering
CEL-SCI Announces Pricing of Public Offering
CEL-SCI Announces Proposed Public Offering
CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CEL-SCI Announces Combination of Common Stock
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia-Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.